Nuvaxovid Xbb.1.5 (Matrix M, Mivalsecovatein)

Matrix M, together with Mivalsecovatein, acts as a recombinant protein antigen. After injection, the antigens are processed by antigen‑presenting cells, which activate B‑cells and T‑cells, leading to the production of specific antibodies and cellular immunity against the targeted virus.

The dosing regimen for Nuvaxovid Xbb.1.5 is determined by the prescribing clinician based on the patient’s age, health status, and the specific indication. Healthcare professionals should follow the latest clinical guidelines and product labeling when prescribing.

Safety data for Nuvaxovid Xbb.1.5 in pregnancy and lactation are limited. Healthcare providers should evaluate the potential benefits and risks before administering the vaccine to pregnant or breastfeeding individuals.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Nuvaxovid Xbb.1.5 uses the proprietary Matrix M and Mivalsecovatein antigens, which differ from traditional inactivated or live‑attenuated vaccines. Its design aims to elicit a broad immune response and may offer advantages in speed of development for emerging viruses, though comparative efficacy depends on the specific pathogen and clinical trial data.

The vaccine must be stored refrigerated between 2 °C and 8 °C. It should be kept in the original packaging, protected from light, and must not be frozen or shaken. Maintaining the cold chain during transport and storage is essential to preserve potency.

Nuvaxovid Xbb.1.5 is given as a single intramuscular injection, typically into the deltoid muscle. Administration should be performed by a qualified healthcare professional using aseptic technique and following local immunization guidelines.

Serious adverse events, although rare, can include anaphylaxis, Guillain‑Barré syndrome, and other severe allergic reactions. Recipients should be observed for at least 15 minutes after injection, and any signs of severe reaction should be treated promptly.

Individuals with a known severe allergy to any component of the vaccine, or those who have experienced a previous severe reaction to a similar vaccine, should avoid receiving Nuvaxovid Xbb.1.5. Clinicians should also assess contraindications in immunocompromised patients on a case‑by‑case basis.